Category C Biological Agents – Emerging Threats in Public Health: Understanding Category “C” Biological Agents and Their Potential for Future Bioterrorism    

Category “C” biological agents occupy a distinct and critical niche in the spectrum of emerging infectious diseases. They are classified as the third-highest priority group of pathogens, not because they pose an immediate threat to global public health, but due to their potential to evolve into significant biological hazards. These agents are primarily emerging pathogens whose epidemiology, pathogenicity, and mechanisms of transmission remain incompletely understood. Despite this uncertainty, Category “C” agents demand proactive attention from public health authorities, biodefense organizations, and the research community because of their accessibility, ease of production, and potential for mass dissemination under certain conditions.

While they have not been widely used in bioterrorism, unlike certain Category A and B pathogens, Category “C” agents can be manipulated or genetically engineered to enhance virulence or transmissibility. Their potential impact is further amplified by their ability to cause severe morbidity and mortality, particularly in vulnerable populations. Many are zoonotic, originating from wildlife or livestock, and may emerge or re-emerge under ecological or environmental pressures, making continuous surveillance essential.

Examples of Category “C” pathogens include severe acute respiratory syndrome (SARS) coronavirus, Hantaviruses, highly pathogenic avian influenza (H5N1), Nipah virus, HIV/AIDS, multidrug-resistant tuberculosis (MDR-TB), and mycotoxin-producing fungi. These agents illustrate the diversity of threats within Category “C,” ranging from viral and bacterial pathogens to biologically active toxins. Their effects may be direct, as in the case of viral hemorrhagic fevers, or indirect, such as the health and economic consequences of mycotoxin contamination.

The public health implications of Category “C” agents are substantial. Surveillance, research, and early detection are critical to identify emerging threats before they escalate. Strengthening laboratory capacity, improving diagnostic tools, and developing effective countermeasures including vaccines and therapeutics are key components of preparedness. Regulatory oversight and biosecurity measures are equally important to prevent accidental or intentional misuse. Integrating epidemiology, molecular biology, ecology, and public health preparedness forms the foundation of effective mitigation. Vigilance, research, and strategic planning today can substantially reduce the likelihood of catastrophic outbreaks or intentional misuse tomorrow.

Defining Category “C” Biological Agents

Category “C” biological agents are characterized by several defining features:

1. Emerging Pathogens: Unlike agents in Categories A and B, which have a history of causing epidemics or have been used as bioweapons, Category “C” pathogens are mostly newly recognized or re-emerging microorganisms. They possess the potential to cause significant morbidity and mortality, but comprehensive epidemiological data is often limited. This knowledge gap complicates risk assessment and public health preparedness.

2. Potential for Future Threat: Although these agents currently pose no immediate bioterrorism or pandemic threat, their evolutionary trajectory, adaptability, and pathogenic potential make them candidates for future concern. As scientific understanding of these microbes expands, previously underestimated risks may materialize.

3. Accessibility and Manipulation: Category “C” agents can often be acquired more readily than higher-tier pathogens. Their production and dissemination, whether through natural processes or genetic engineering, are feasible in laboratory settings, which raises concerns about intentional misuse.

4. High Morbidity and Mortality Potential: Many Category “C” pathogens can cause severe disease, particularly in immunocompromised populations or under specific ecological or epidemiological conditions. The consequences of infection can be profound at both individual and population levels.

5. Information Gaps: Our understanding of these agents’ pathogenic mechanisms, transmission dynamics, and population-level effects is often incomplete. Limited surveillance, diagnostic challenges, and underreporting contribute to uncertainty regarding their true burden.

Epidemiological and Pathogenic Considerations for Category C Agents

Emerging infectious diseases often arise at the interface of human activity and ecological disruption. Zoonotic spillover, environmental changes, and globalization increase the likelihood of these pathogens evolving into threats. 

For Category “C” agents, several epidemiological characteristics are noteworthy:

• Zoonotic Reservoirs: Many Category “C” pathogens are zoonoses, originating in animal hosts before crossing into human populations. The Nipah virus, for instance, is transmitted from bats to humans through intermediate hosts such as pigs or via direct exposure to contaminated materials. Similarly, Hantaviruses circulate in rodent populations and occasionally infect humans through inhalation of contaminated excreta.

• Viral Evolution and Antigenic Drift: Influenza A (H5N1) exemplifies the potential for rapid evolution. Avian influenza viruses can undergo genetic reassortment, creating novel strains with pandemic potential. Continuous surveillance of these viruses is essential to anticipate emergent threats.

• Antimicrobial Resistance: Multidrug-resistant tuberculosis (MDR-TB) represents a bacterial Category “C” threat where pathogen evolution and human medical practices intersect. Resistance to frontline drugs makes outbreaks difficult to control and increases mortality, highlighting the public health significance even absent bioterrorism use.

• Chronic and Immunosuppressive Effects: HIV/AIDS is a Category “C” pathogen of global significance. Its long incubation period, immune system suppression, and persistence in human populations illustrate how Category “C” agents may exert prolonged impacts, complicating both surveillance and response strategies.

• Toxigenic Potential: Some Category “C” agents produce potent toxins rather than relying solely on infectious propagation. Mycotoxin-producing fungi, for example, contaminate food or feed and can cause mass morbidity in human and animal populations. This indirect pathogenicity is a unique feature of certain Category “C” threats.

Examples of Category “C” Biological Agents

Severe Acute Respiratory Syndrome (SARS)

SARS is caused by the SARS coronavirus (SARS-CoV), an enveloped positive-sense RNA virus belonging to the Coronaviridae family. Its genome encodes structural proteins including spike (S), envelope (E), membrane (M), and nucleocapsid (N), which mediate viral entry, assembly, and immune evasion. SARS-CoV primarily infects respiratory epithelial cells via the angiotensin-converting enzyme 2 (ACE2) receptor, causing severe lower respiratory tract disease. The virus emerged in 2002-2003, likely originating from bats with civet cats as intermediate hosts before spillover to humans. Transmission occurs through respiratory droplets, aerosols, and direct contact with contaminated surfaces, with high infectivity in healthcare and close-contact settings. Detection relies on RT-PCR for viral RNA, serological assays for antibodies, and chest imaging to assess lung involvement. There is no specific antiviral therapy; management is supportive, including oxygen supplementation, fluid management, and mechanical ventilation when necessary. Controlrelies on rapid case isolation, contact tracing, quarantine, and strict infection control in healthcare facilities. Continued monitoring of wildlife reservoirs is essential because SARS-CoV can persist in bats, posing a risk of re-emergence. The outbreak underscored the importance of global surveillance, rapid diagnostics, and coordinated public health response to emerging viral threats.

Hantaviruses

Hantaviruses are negative-sense single-stranded RNA viruses of the Hantaviridae family, causing hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus pulmonary syndrome (HPS) in the Americas. The virus primarily infects endothelial cells, increasing vascular permeability and leading to severe hemorrhagic or pulmonary manifestations. Humans are incidental hosts, typically infected via inhalation of aerosolized excreta, urine, or saliva from infected rodents. Rodent species, such as deer mice (Peromyscus maniculatus), serve as natural reservoirs and maintain the virus without illness. Transmission is generally sporadic but can result in clusters in rural or occupational settings. Detection involves serological assays (ELISA) for IgM and IgG antibodies, RT-PCR for viral RNA, and immunohistochemistry for tissue samples. There is no FDA-approved antiviral therapy for most hantaviruses; treatmentis primarily supportive, including intensive care for respiratory or renal failure. Preventive measures focus on rodent control, minimizing exposure to rodent habitats, and public education. Ecological surveillance is critical, as environmental changes, such as deforestation or increased human-rodent contact, can drive outbreaks. Hantaviruses exemplify the potential for wildlife-origin pathogens to cross species barriers and cause severe human disease.

Influenza A (H5N1)

Influenza A H5N1 is a highly pathogenic avian influenza virus of the Orthomyxoviridae family, with a segmented negative-sense RNA genome that allows for reassortment and antigenic shift. Its hemagglutinin (HA) protein mediates viral entry into host epithelial cells, while neuraminidase (NA) facilitates release of progeny virions. H5N1 circulates primarily in wild and domestic birds and occasionally infects humans through direct contact with infected poultry or contaminated environments. Human-to-human transmission is limited but possible under certain conditions. Infection can result in severe respiratory illness with high mortality rates, often exceeding 50% in reported cases. Detection relies on RT-PCR, viral culture, and serology. Treatment options include neuraminidase inhibitors (oseltamivir, zanamivir) if administered early, along with supportive care. Control measures focus on culling infected poultry, biosecurity in farms, vaccination of birds in high-risk areas, and monitoring migratory bird populations. H5N1’s propensity for genetic reassortment with other influenza viruses makes it a persistent Category “C” threat, as novel strains with enhanced transmissibility could emerge. Surveillance, rapid diagnostics, and international collaboration are essential to prevent potential outbreaks or bioterror misuse.

Nipah Virus

Nipah virus (NiV) is an enveloped, negative-sense single-stranded RNA virus in the Henipavirus genus, causing severe encephalitis and respiratory disease in humans. Fruit bats (Pteropus species) are the natural reservoir, with transmission occurring to humans via direct contact with infected bats, intermediate hosts such as pigs, or consumption of contaminated fruits and sap. Limited human-to-human transmission has been documented, primarily in healthcare settings. After infection, the virus targets endothelial cells and neurons, leading to systemic vasculitis and central nervous system damage. Detection methods include RT-PCR, virus isolation, and serological tests for IgM and IgG antibodies. No approved antivirals or vaccines exist for humans; treatment is supportive, focusing on intensive care management for respiratory and neurological complications. Control strategies include reducing bat-livestock-human contact, implementing safe farming practices, isolating infected patients, and educating communities on transmission risks. Nipah virus outbreaks are characterized by high mortality, sometimes exceeding 70%, and rapid progression of illness. Ongoing surveillance of bat populations and livestock, coupled with public health preparedness, is critical to prevent re-emergence or potential exploitation in bioterrorism scenarios.

HIV/AIDS

Human immunodeficiency virus (HIV) is a retrovirus that targets CD4+ T lymphocytes, leading to progressive immunodeficiency. Two main types, HIV-1 and HIV-2, differ in global prevalence and pathogenicity, with HIV-1 responsible for the majority of global infections. Transmission occurs through sexual contact, blood transfusions, sharing of contaminated needles, and vertical transmission from mother to child. The virus integrates into host DNA via reverse transcription, establishing chronic infection with a prolonged latent period. Detection involves serological assays for antibodies (ELISA, Western blot), antigen testing (p24), and nucleic acid amplification tests for viral RNA. While no cure exists, antiretroviral therapy (ART) suppresses viral replication, restores immune function, and reduces transmission risk. Preventive strategies include condom use, safe blood transfusion practices, needle exchange programs, pre-exposure prophylaxis (PrEP), and mother-to-child transmission prevention. HIV/AIDS remains a Category “C” pathogen because its long-term impact on global health, immunosuppressive effects, and ongoing transmission dynamics represent persistent public health challenges despite widespread awareness and interventions.

Multidrug-Resistant Tuberculosis (MDR-TB)

MDR-TB is caused by Mycobacterium tuberculosis strains resistant to at least isoniazid and rifampicin, the two most effective first-line drugs. This pathogen infects alveolar macrophages, leading to chronic pulmonary disease and potential extrapulmonary involvement. Transmission occurs via inhalation of aerosolized droplets from individuals with active pulmonary TB. Detection includes sputum smear microscopy, culture, molecular assays (Xpert MTB/RIF), and drug susceptibility testing. Treatment requires prolonged regimens with second-line drugs, often including fluoroquinolones and injectable agents, which are less effective, more toxic, and costly. Control strategies emphasize early diagnosis, adherence to therapy, contact tracing, vaccination with Bacille Calmette-Guérin (BCG) in endemic regions, and public health measures to limit transmission. MDR-TB exemplifies how microbial evolution, combined with incomplete treatment adherence, can escalate naturally occurring pathogens into high-impact public health threats, underscoring the need for global surveillance and antimicrobial stewardship.

Mycotoxin-Producing Fungi

Mycotoxin-producing fungi, such as Aspergillus, Fusarium, and Penicillium species, secrete secondary metabolites toxic to humans and animals. Common mycotoxins include aflatoxins, ochratoxins, and fumonisins, which target the liver, kidneys, and nervous system. Exposure occurs primarily through ingestion of contaminated crops, stored grains, or animal-derived food products. Fungal colonization is favored by warm, humid conditions, poor storage, and agricultural practices. Detection involves chromatographic techniques (HPLC, LC-MS), immunoassays, and molecular assays for toxin-producing gene clusters. Treatment is largely supportive and symptom-directed; for acute poisoning, activated charcoal and liver-protective interventions may be used. Control emphasizes agricultural hygiene, proper drying and storage of crops, monitoring food supplies, and regulatory limits on allowable toxin concentrations. These fungi illustrate that Category “C” threats are not restricted to viruses or bacteria but include biologically active compounds capable of widespread morbidity and indirect population-level impact.

Potential of Category C Pathogens for Bioterrorism

Although Category “C” pathogens have not been widely weaponized, several features make them relevant in the context of biodefense:

1. Ease of Acquisition and Production: Many Category “C” agents are present in natural reservoirs or laboratory collections, making them more accessible than select Category A pathogens. Advances in synthetic biology further increase the potential for genetic engineering to enhance virulence or environmental stability.

2. Genetic Engineering and Amplification: Emerging pathogens can be modified to increase pathogenicity, transmissibility, or resistance to existing therapeutics. While highly regulated, such manipulations are technically feasible, highlighting the dual-use dilemma inherent in Category “C” research.

3. High Impact Potential: Even if dissemination occurs on a limited scale, the morbidity, mortality, or social disruption caused by Category “C” agents could be substantial. The indirect effects, including economic impact, public panic, and strain on healthcare systems, amplify the potential consequences.

4. Integration into Surveillance Programs: Effective preparedness involves not only understanding the natural ecology of these agents but also developing countermeasures, including rapid diagnostics, therapeutics, and vaccines. Anticipatory strategies are critical to reduce vulnerability to both natural outbreaks and intentional release.

Public Health Implications

Understanding and mitigating the risks posed by Category “C” agents requires an integrated, multidisciplinary approach. The following practical strategies can be implemented to prevent or reduce the potential threats of category C pathogens:

• Surveillance and Early Detection: Strengthening disease surveillance, particularly at the wildlife human interface, is essential. Real-time genomic monitoring can detect novel variants before they pose widespread threats.

• Research and Knowledge Expansion: Detailed studies on pathogen biology, transmission, and host-pathogen interactions reduce uncertainty. This knowledge informs vaccine development, therapeutic strategies, and risk modeling.

• Preparedness and Response Planning: Public health systems must plan for high-consequence but low-probability events. Scenario-based exercises and stockpiling of relevant medical countermeasures improve readiness for both natural and intentional outbreaks.

• Regulatory Oversight and Biosecurity: Laboratory access, dual-use research, and pathogen handling protocols require stringent oversight. Ethical and legal frameworks must balance scientific advancement with security considerations.

• Global Collaboration: Emerging pathogens know no borders. International cooperation in surveillance, data sharing, and outbreak response is crucial to mitigating Category “C” threats.

     

References

Aschengrau A and Seage G.R (2013). Essentials of Epidemiology in Public Health. Third edition. Jones and Bartleh Learning,

Aschengrau, A., & G. R. Seage III. (2009). Essentials of Epidemiology in Public Health.  Boston:  Jones and Bartlett Publishers.

Castillo-Salgado C (2010). Trends and directions of global public health surveillance. Epidemiol Rev, 32:93–109.

Centers for Disease Control and National Institutes of Health (1999). Biosafety in Microbiological and Biomedical Laboratories, 4th edn, Washington DC: CDC.

Guillemin J (2006). Scientists and the history of biological weapons. European Molecular Biology Organization (EMBO) Reports, Vol 7, Special Issue: S45-S49.

Halliday JE, Meredith AL, Knobel DL, Shaw DJ, Bronsvoort BMC, Cleaveland S (2007). A framework for evaluating animals as sentinels for infectious disease surveillance. J R Soc Interface, 4:973–984.

Nelson K.E and Williams C (2013). Infectious Disease Epidemiology: Theory and Practice. Third edition. Jones and Bartleh Learning. 

Porta M (2008). A dictionary of epidemiology. 5^th edition. New York: Oxford University Press.

Rothman K.J and Greenland S (1998). Modern epidemiology, 2^nd edition. Philadelphia: Lippincott-Raven. 

Rothman K.J, Greenland S and Lash T.L (2011). Modern Epidemiology. Third edition. Lippincott Williams and Wilkins, Philadelphia, PA, USA.